NASDAQ : SABS
SAB Biotherapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 3.35 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 304.80M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 304.80M |
| Enterprise Value | 207.30M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 90.99M |
| Shares Outstanding | 90.99M |
| Shares Change (YoY) | +417.54% |
| Shares Change (QoQ) | +48.91% |
| Owned by Insiders (%) | 0.65% |
| Owned by Institutions (%) | 45.11% |
| Float | 62.04M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.30 |
| P/TBV Ratio | 1.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 9.22 |
| Quick Ratio | 8.93 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -310.04 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -11.27% |
| Return on Assets (ROA) | -33.46% |
| Return on Invested Capital (ROIC) | -37.67% |
| Return on Capital Employed (ROCE) | -31.71% |
| Weighted Average Cost of Capital (WACC) | 7.40% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$253,346 |
| Employee Count | 86 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.58 |
| 52-Week Price Change | +10.20% |
| 50-Day Moving Average | 3.26 |
| 200-Day Moving Average | 3.68 |
| Relative Strength Index (RSI) | 60.17 |
| Average Volume (20 Days) | 685,360 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 4.80M |
| Short Previous Month | 4.29M |
| Short % of Shares Out | 5.28% |
| Short % of Float | 7.74% |
| Short Ratio (days to cover) | 6.28 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -48.27M |
| Operating Income | -71.82M |
| Pretax Income | -12.78M |
| Net Income | -21.79M |
| EBITDA | -68.71M |
| EBIT | -71.82M |
| Earnings Per Share (EPS) | -$1.56 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 102.63M |
| Total Debt | 5.13M |
| Net Cash | 97.50M |
| Net Cash Per Share | $1.07 |
| Equity (Book Value) | 214.79M |
| Book Value Per Share | 2.57 |
| Working Capital | 96.23M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -53.94M |
| Capital Expenditures | -3.50M |
| Depreciation & Amortization | 3.12M |
| Net Borrowing | -148,412 |
| Free Cash Flow | -57.44M |
| FCF Per Share | -$0.63 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -417.54% |
| Shareholder Yield | -417.54% |
| Earnings Yield | -46.45% |
| FCF Yield | -18.84% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $11.64 |
| Price Target Difference | 247.46% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jan 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |